The technology uses light-sensitive proteins to activate or inhibit nerve cells with millisecond precision. Its application is expanding knowledge about memory and behavior, and has opened a new experimental pathway to restore partial vision in people with certain retinal diseases.
The human brain contains billions of neurons connected to each other through circuits of extraordinary complexity. Understanding how these connections are organized, what role each group of cells plays, and how their activity influences memory, emotions, or behavior constitutes one of the great challenges of neuroscience. Optogenetics has provided researchers with a tool to address these questions with a degree of precision that until a few decades ago was difficult to imagine.
The breakthrough has received the 2026 Nobel Prize in Physiology or Medicine, awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for their discoveries related to light-sensitive ion channels and the development of optogenetics. Their work connected a finding from algae biology with a technology capable of experimentally modifying the activity of specific neurons.
The relevance of the discovery lies in a possibility essential for research: intervening in a defined brain circuit and observing what happens when its activity is activated or inhibited. This capability allows studying causal relationships between neuronal activity and a specific function, a fundamental step toward understanding the mechanisms involved in cognitive processes and neurological diseases.
From a microalga to brain circuits
The origin of this technology lies in Chlamydomonas reinhardtii, a single-celled microalga that uses light to orient itself in its environment. Researchers identified proteins in its membrane capable of responding to illumination and allowing the passage of ions through it.
Among these proteins, channelrhodopsin stands out, especially channelrhodopsin-2, known as ChR2. Upon receiving light of an appropriate wavelength, this protein opens a channel that allows the passage of electrically charged ions. The movement of these ions modifies the electrical potential of the cell membrane.
Peter Hegemann and Georg Nagel contributed decisively to discovering and characterizing these proteins. Karl Deisseroth and other researchers later developed methods to introduce the genes encoding photosensitive proteins into mammalian neurons. In this way, nerve cells could respond to light stimuli administered in a controlled manner.
The combination of genetics and light gave rise to optogenetics. The procedure consists, in simplified terms, of introducing via a genetic vector the necessary material for certain cells to produce a photosensitive opsin. Once the protein is expressed in the membrane, researchers can illuminate the cells with a specific wavelength and modify their electrical activity.
The first decisive demonstrations in mammalian neurons came in 2005. Since then, the technique has made it possible to investigate neural circuits with a temporal and spatial precision that complements other methods of brain recording and stimulation.
Turning on or inhibiting neuronal activity
Optogenetics offers different possibilities depending on the photosensitive protein used. Some opsins, such as ChR2, allow the entry of positive ions and promote membrane depolarization, increasing the probability that the neuron generates electrical impulses. Others, such as halorhodopsin, can promote the entry of chloride ions and reduce the probability of neuronal activation.
The choice of protein and lighting conditions determines the effect. Therefore, applying light alone is not enough: researchers must select the appropriate molecular system, control gene expression, and establish precise stimulation parameters.
Light can be administered through optical fibers or other devices designed to reach the selected cells. The response is measured through recordings of neuronal activity and behavioral observations, which allows relating the intervention to its consequences.
This combination is especially valuable because brain activity depends on networks of neurons that cooperate and interact. Observing a correlation between the activation of a region and a behavior provides information, but experimentally modifying a cell group and verifying the result allows progress toward a causal explanation.
What it can reveal about memory and behavior
One of the most relevant applications of optogenetics is found in the study of memory. In 2012, research published in Nature demonstrated that the reactivation of previously identified neurons in the hippocampus of mice could trigger a freezing response associated with a memory learned through fear conditioning.
The experiment helped show that the activation of a neuronal ensemble related to an experience could retrieve a behavioral response linked to that memory. This type of research allows exploring how memories are encoded and retrieved, which circuits participate in learning, and how neuronal connections change with experience.
The results are also of interest for investigating the mechanisms of fear, anxiety, and certain processes related to psychiatric disorders. However, activating a circuit associated with a memory in a laboratory animal is not equivalent to erasing, editing, or controlling human memories at will. Memory is a distributed and dynamic process, and its functioning depends on multiple networks and interaction with other brain processes.
The technique makes it possible to formulate and test hypotheses about these mechanisms. Its clinical value will depend on whether that knowledge translates into safe, effective, and reproducible interventions.
A human application: restoring part of vision
Optogenetics has also begun to be explored outside experimental brain research. One of the most notable clinical results was published in 2021 in Nature Medicine: a patient with advanced retinitis pigmentosa partially regained the ability to perceive certain objects through an optogenetic therapy combined with special glasses.
Retinitis pigmentosa comprises degenerative diseases of the retina that cause the progressive loss of photoreceptors, the cells responsible for capturing light. The strategy studied consisted of introducing into certain retinal ganglion cells the gene for a light-sensitive opsin called ChrimsonR. These cells can transmit visual information to the brain, although they normally do not perform the function of photoreceptors.
The patient received an intraocular injection of a viral vector carrying the gene and used glasses capable of capturing the visual scene and projecting light patterns onto the treated retina. The stimulation made it possible to activate the modified cells and generate signals that reached the visual areas of the brain.
With the system, the patient was able to perceive, locate, count, and touch some objects using the treated eye. The researchers also recorded activity related to visual perception in the cerebral cortex.
The result was significant, although its scope should be described precisely: it was a partial functional recovery in a single patient, with the help of an external device. It did not mean the restoration of normal vision, nor does it demonstrate that the technique can be broadly applied to all forms of blindness. The study constituted a clinical proof of concept that requires further research to determine its efficacy, safety, and applicability.
From research to medicine
The potential of optogenetics depends on its ability to identify the circuits involved in a function and to verify how that function changes when its activity is modified. This information can help to better understand neurological and psychiatric diseases, as well as guide the development of new therapeutic strategies.
Its clinical use, however, presents significant challenges. The intervention typically requires introducing genetic material into target cells, achieving adequate expression of the photosensitive proteins, and delivering light with sufficient precision. In the brain, reaching specific neuronal populations poses additional challenges related to tissue depth and the need for stimulation devices.
The visual therapy published in 2021 illustrates both the possibilities and the current limitations: it was necessary to combine a genetic intervention with a specific optical system and visual training. The strategy did not simply consist of illuminating the retina, but rather of endowing certain cells with a new sensitivity to light.
Optogenetics should also not be confused with photobiomodulation techniques, which use light to study or modulate biological processes without necessarily introducing photosensitive proteins through genetic engineering. Although both employ light stimuli, their mechanisms, objectives, and applications are different.
The Nobel recognition highlights the importance of basic research in opening new avenues in medicine. The discovery of a protein in a microalga made it possible to develop a tool that today helps study some of the most complex processes of the nervous system. Its immediate contribution consists of offering science a more precise way to investigate how the brain works; its future therapeutic applications will depend on the results of clinical studies and the ability to convert that knowledge into safe and effective treatments.
Scientific sources
- Nobel Prize: recognition of Karl Deisseroth, Peter Hegemann, and Georg Nagel for their discoveries regarding light-sensitive ion channels and optogenetics.
- Sahel, J.-A. et al. “Partial recovery of visual function in a blind patient after optogenetic therapy”. Nature Medicine, 2021. DOI: 10.1038/s41591-021-01351-4.
- Deisseroth, K. et al. Foundational research on optical control of neuronal activity, published in Nature Neuroscience in 2005.
- Research on the reactivation of hippocampal neuronal ensembles and the recovery of learned fear responses, published in Nature in 2012.
